Review of proposed ergothioneine mechanisms

Editorial study summary

Study type

Systematic review with network pharmacology.

Product relevance

Mechanistic and ingredient-level context.

Sample or population

Literature published from 2005 to 2025. The number of included studies is not reported in the abstract.

Studied dose

Varied across sources. No common dose is reported in the abstract.

Duration

Varied across sources.

Finding

The review describes transporter-mediated distribution and discusses hypotheses involving mitochondria, telomeres and NRF2 signalling. The authors identify gaps in clinical testing.

Limitations

Mechanistic and longitudinal evidence cannot establish longer human healthspan or clinical benefit.

Study quality

The abstract identifies the review as systematic but gives limited detail on its methods. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.

Funding and disclosures

The PubMed disclosure reports no known competing interests. Funding was not verified.

The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.

Reference

1. Ergothioneine as a potential geroprotector: Targeting molecular hallmarks of ageing and age-related diseases. Ageing Res Rev. 2026. DOI 10.1016/j.arr.2026.103158. PMID 42107722